BILL ANALYSIS

HR7895

NEUTRAL

PBM Kickback Prohibition Act

HR7895 (PBM Kickback Prohibition Act) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

2/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR7895 is early-stage, low-priority legislation with near-zero passage probability this Congress.

The bill targets a narrow, non-core PBM revenue stream — referral compensation — not drug pricing or rebates.

Even if enacted, financial impact on CVS, UNH, and CI would be immaterial relative to total revenues.

Current market rallies in CVS (+16% 30-day), UNH (+36%), and CI (+10%) are unrelated to this bill.

How HR7895 Affects the Market

No material market implication from this bill. CVS at $83.41, UNH at $368.70, and CI at $292.30 have rallied strongly over the past 30 days on earnings and sector dynamics — not on any PBM regulatory shift. This bill is not a catalyst for any of the three tickers. The 52-week ranges show CVS near its high, UNH well off its low but below its high of $411.99, and CI in the middle of its range. Investors should not factor this bill into positions on any of these stocks.

Bill Details

Metric	Value
Bill Number	HR7895
Market Sentiment	neutral
Event Date	March 12, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR7895 is an early-stage House bill banning referral compensation to PBMs. It has no Senate companion, sits at the start of the legislative process, and has near-zero passage probability in this Congress. Market data shows the three largest PBM-associated stocks (CVS, UNH, CI) have rallied significantly over the past 30 days — this bill is not a driver of those moves. The bill's impact, if enacted, would be immaterial to all three companies' financials.

Full AI Market Analysis

What happened: On March 12, 2026, Rep. Rick Allen (R-GA) introduced H.R. 7895, the PBM Kickback Prohibition Act. The bill amends ERISA Section 408 to bar pharmacy benefit managers from paying compensation to brokers or advisors for the referral of plan business. The bill was referred to the House Committee on Education and Workforce. As of April 30, 2026, no further action has occurred — no hearings, markup, or Senate companion bill. The money trail: The bill authorizes $0 in federal spending. It imposes a regulatory prohibition on private sector payment arrangements. No taxpayer funds are involved. No appropriations process is required. The economic effect is purely a removal of a specific private payment stream between PBMs and referral intermediaries. Structural winners and losers: This bill, if enacted, would theoretically reduce one very narrow cost stream for the three largest PBMs — CVS Caremark, Optum Rx, and Express Scripts. However, referral compensation is a minor, non-core revenue source. None of these companies break out referral fees as a material segment driver. The actual competitive positioning of these PBMs is driven by formulary management, rebate negotiation, and pharmacy network breadth — none of which this bill touches. Real market data context: Over the past 30 days (March 31 to April 30, 2026), has risen 16.12%, has surged 36.26%, and has gained 9.58%. These moves are driven by earnings, sector rotation, or other market factors — not by this bill. The bill was introduced on March 12 and has generated zero price reaction. At $83.41, is trading near its 52-week high of $85.15. at $368.70 is well above its 52-week low of $234.60. at $292.30 sits roughly in the middle of its 52-week range. The 30-day rallies predate and post-date the bill's introduction without any visible inflection. Timeline: The bill is at the earliest stage of the legislative process — introduced, referred to committee, no schedule for hearing or markup. With no Senate companion and limited sponsor seniority (Rep. Allen is a junior House Republican), the probability of enactment in the 119th Congress is near zero. Even if it moved, the effective date applies only to plan years beginning after enactment, meaning any real-world impact would be years away.